Aspire Biopharma Holdings, Inc.
ASBP
$8.87
-$0.38-4.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 60.65% | 31.54% | -154.40% | 6.60% | 87.57% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -100.00% | -73.59% | 196.76% | -- | -- |
| Total Other Non-Cash Items | -13,360.23% | 100.28% | -94.62% | -234.83% | -91.86% |
| Change in Net Operating Assets | 122.68% | -259.74% | 176.92% | 193.54% | -4.32% |
| Cash from Operations | 30.37% | -227.50% | 15.94% | 3.20% | 34.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | -100.00% | -- | -100.00% |
| Total Debt Repaid | 83.68% | -18,442.42% | 99.53% | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.55% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 39.89% | -- | -100.00% |
| Cash from Financing | 6.77% | 47,927.88% | -100.58% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.02% | 613.88% | -154.21% | 252.77% | -184.91% |